Fulcrum Therapeutics, Inc.
FULC
$6.68
$0.162.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | 3,087.25% | 2,752.05% | 2,987.86% | 2,582.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | 3,087.25% | 2,752.05% | 2,987.86% | 2,582.55% |
| Cost of Revenue | -28.99% | -23.83% | -11.72% | -0.98% | 8.43% |
| Gross Profit | -816.71% | 131.77% | 124.08% | 114.84% | 111.24% |
| SG&A Expenses | -25.33% | -16.97% | -12.53% | -7.96% | -3.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.70% | -21.44% | -12.02% | -3.56% | 3.84% |
| Operating Income | -152.36% | 90.76% | 82.08% | 74.34% | 69.41% |
| Income Before Tax | -261.84% | 99.49% | 90.01% | 81.85% | 79.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -261.84% | 99.49% | 90.01% | 81.85% | 79.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -261.84% | 99.49% | 90.01% | 81.85% | 79.44% |
| EBIT | -152.36% | 90.76% | 82.08% | 74.34% | 69.41% |
| EBITDA | -163.20% | 91.91% | 83.19% | 75.41% | 70.53% |
| EPS Basic | -266.26% | 97.10% | 87.57% | 82.81% | 81.75% |
| Normalized Basic EPS | -256.30% | 99.16% | 89.65% | 84.77% | 81.65% |
| EPS Diluted | -245.79% | 95.48% | 85.94% | 81.46% | 80.52% |
| Normalized Diluted EPS | -236.63% | 97.96% | 88.44% | 83.63% | 80.58% |
| Average Basic Shares Outstanding | -2.62% | -2.60% | -1.90% | 5.54% | 12.77% |
| Average Diluted Shares Outstanding | -3.16% | -2.04% | -1.34% | 6.13% | 13.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |